<?xml version='1.0' encoding='utf-8'?>
<document id="26522231"><sentence text="Effect of long-term coadministration of compound glycyrrhizin tablets on the pharmacokinetics of mycophenolic acid in rats."><entity charOffset="49-61" id="DDI-PubMed.26522231.s1.e0" text="glycyrrhizin" /><entity charOffset="97-114" id="DDI-PubMed.26522231.s1.e1" text="mycophenolic acid" /><pair ddi="false" e1="DDI-PubMed.26522231.s1.e0" e2="DDI-PubMed.26522231.s1.e0" /><pair ddi="false" e1="DDI-PubMed.26522231.s1.e0" e2="DDI-PubMed.26522231.s1.e1" /></sentence><sentence text="1" /><sentence text=" Mycophenolic acid (MPA), having high-protein affinity, is an immunodepressant and the genuine-active ingredient of enteric-coated mycophenolate sodium (EC-MPS) tablet that has been widely used in combination with tacrolimus or cyclosporine to prevent acute rejection after organ transplantation"><entity charOffset="20-23" id="DDI-PubMed.26522231.s3.e0" text="MPA" /><entity charOffset="131-151" id="DDI-PubMed.26522231.s3.e1" text="mycophenolate sodium" /><entity charOffset="153-159" id="DDI-PubMed.26522231.s3.e2" text="EC-MPS" /><entity charOffset="214-224" id="DDI-PubMed.26522231.s3.e3" text="tacrolimus" /><entity charOffset="228-240" id="DDI-PubMed.26522231.s3.e4" text="cyclosporine" /><pair ddi="false" e1="DDI-PubMed.26522231.s3.e0" e2="DDI-PubMed.26522231.s3.e0" /><pair ddi="false" e1="DDI-PubMed.26522231.s3.e0" e2="DDI-PubMed.26522231.s3.e1" /><pair ddi="false" e1="DDI-PubMed.26522231.s3.e0" e2="DDI-PubMed.26522231.s3.e2" /><pair ddi="false" e1="DDI-PubMed.26522231.s3.e0" e2="DDI-PubMed.26522231.s3.e3" /><pair ddi="false" e1="DDI-PubMed.26522231.s3.e0" e2="DDI-PubMed.26522231.s3.e4" /><pair ddi="false" e1="DDI-PubMed.26522231.s3.e1" e2="DDI-PubMed.26522231.s3.e1" /><pair ddi="false" e1="DDI-PubMed.26522231.s3.e1" e2="DDI-PubMed.26522231.s3.e2" /><pair ddi="false" e1="DDI-PubMed.26522231.s3.e1" e2="DDI-PubMed.26522231.s3.e3" /><pair ddi="false" e1="DDI-PubMed.26522231.s3.e1" e2="DDI-PubMed.26522231.s3.e4" /><pair ddi="false" e1="DDI-PubMed.26522231.s3.e2" e2="DDI-PubMed.26522231.s3.e2" /><pair ddi="false" e1="DDI-PubMed.26522231.s3.e2" e2="DDI-PubMed.26522231.s3.e3" /><pair ddi="false" e1="DDI-PubMed.26522231.s3.e2" e2="DDI-PubMed.26522231.s3.e4" /><pair ddi="false" e1="DDI-PubMed.26522231.s3.e3" e2="DDI-PubMed.26522231.s3.e3" /><pair ddi="false" e1="DDI-PubMed.26522231.s3.e3" e2="DDI-PubMed.26522231.s3.e4" /></sentence><sentence text=" Moreover, MPA mainly experiences glucuronidation and its metabolites are partly transported by multidrug resistance-associated protein (Mrp) 2 into bile then reforms MPA via enterohepatic circulation"><entity charOffset="11-22" id="DDI-PubMed.26522231.s4.e0" text="MPA" /><entity charOffset="167-178" id="DDI-PubMed.26522231.s4.e1" text="MPA" /><pair ddi="false" e1="DDI-PubMed.26522231.s4.e0" e2="DDI-PubMed.26522231.s4.e0" /><pair ddi="false" e1="DDI-PubMed.26522231.s4.e0" e2="DDI-PubMed.26522231.s4.e1" /></sentence><sentence text=" 2" /><sentence text=" Glycyrrhizin (GL), having high-protein affinity, is the main active ingredient of compound glycyrrhizin tablet, which is often prescribed with EC-MPS, tacrolimus or cyclosporine to prevent drug-induced hepatitis"><entity charOffset="0-13" id="DDI-PubMed.26522231.s6.e0" text=" Glycyrrhizin" /><entity charOffset="15-17" id="DDI-PubMed.26522231.s6.e1" text="GL" /><entity charOffset="92-104" id="DDI-PubMed.26522231.s6.e2" text="glycyrrhizin" /><entity charOffset="144-150" id="DDI-PubMed.26522231.s6.e3" text="EC-MPS" /><entity charOffset="152-162" id="DDI-PubMed.26522231.s6.e4" text="tacrolimus" /><entity charOffset="166-178" id="DDI-PubMed.26522231.s6.e5" text="cyclosporine" /><pair ddi="false" e1="DDI-PubMed.26522231.s6.e0" e2="DDI-PubMed.26522231.s6.e0" /><pair ddi="false" e1="DDI-PubMed.26522231.s6.e0" e2="DDI-PubMed.26522231.s6.e1" /><pair ddi="false" e1="DDI-PubMed.26522231.s6.e0" e2="DDI-PubMed.26522231.s6.e2" /><pair ddi="false" e1="DDI-PubMed.26522231.s6.e0" e2="DDI-PubMed.26522231.s6.e3" /><pair ddi="false" e1="DDI-PubMed.26522231.s6.e0" e2="DDI-PubMed.26522231.s6.e4" /><pair ddi="false" e1="DDI-PubMed.26522231.s6.e0" e2="DDI-PubMed.26522231.s6.e5" /><pair ddi="false" e1="DDI-PubMed.26522231.s6.e1" e2="DDI-PubMed.26522231.s6.e1" /><pair ddi="false" e1="DDI-PubMed.26522231.s6.e1" e2="DDI-PubMed.26522231.s6.e2" /><pair ddi="false" e1="DDI-PubMed.26522231.s6.e1" e2="DDI-PubMed.26522231.s6.e3" /><pair ddi="false" e1="DDI-PubMed.26522231.s6.e1" e2="DDI-PubMed.26522231.s6.e4" /><pair ddi="false" e1="DDI-PubMed.26522231.s6.e1" e2="DDI-PubMed.26522231.s6.e5" /><pair ddi="false" e1="DDI-PubMed.26522231.s6.e2" e2="DDI-PubMed.26522231.s6.e2" /><pair ddi="false" e1="DDI-PubMed.26522231.s6.e2" e2="DDI-PubMed.26522231.s6.e3" /><pair ddi="false" e1="DDI-PubMed.26522231.s6.e2" e2="DDI-PubMed.26522231.s6.e4" /><pair ddi="false" e1="DDI-PubMed.26522231.s6.e2" e2="DDI-PubMed.26522231.s6.e5" /><pair ddi="false" e1="DDI-PubMed.26522231.s6.e3" e2="DDI-PubMed.26522231.s6.e3" /><pair ddi="false" e1="DDI-PubMed.26522231.s6.e3" e2="DDI-PubMed.26522231.s6.e4" /><pair ddi="false" e1="DDI-PubMed.26522231.s6.e3" e2="DDI-PubMed.26522231.s6.e5" /><pair ddi="false" e1="DDI-PubMed.26522231.s6.e4" e2="DDI-PubMed.26522231.s6.e4" /><pair ddi="false" e1="DDI-PubMed.26522231.s6.e4" e2="DDI-PubMed.26522231.s6.e5" /></sentence><sentence text=" In addition, GL can inhibit Mrp2 and selectively induce CYP3A and UGTs; and it also undergoes enterohepatic circulation"><entity charOffset="14-25" id="DDI-PubMed.26522231.s7.e0" text="GL" /></sentence><sentence text=" 3" /><sentence text=" After 14 days of coadministration of compound GL tablets with the capsules of EC-MPS tablets, the AUC0-48 h of total and free MPA was dramatically increased, and the clearance of total and free MPA was apparently decreased"><entity charOffset="127-128" id="DDI-PubMed.26522231.s9.e0" text="MPA" /><entity charOffset="195-196" id="DDI-PubMed.26522231.s9.e1" text="MPA" /><entity charOffset="47-48" id="DDI-PubMed.26522231.s9.e2" text="GL" /><pair ddi="false" e1="DDI-PubMed.26522231.s9.e2" e2="DDI-PubMed.26522231.s9.e2" /><pair ddi="false" e1="DDI-PubMed.26522231.s9.e2" e2="DDI-PubMed.26522231.s9.e0" /><pair ddi="false" e1="DDI-PubMed.26522231.s9.e2" e2="DDI-PubMed.26522231.s9.e1" /><pair ddi="false" e1="DDI-PubMed.26522231.s9.e0" e2="DDI-PubMed.26522231.s9.e0" /><pair ddi="false" e1="DDI-PubMed.26522231.s9.e0" e2="DDI-PubMed.26522231.s9.e1" /></sentence><sentence text=" It would seem reasonable that our data appear to support further investigation of this drug-drug interactions in the clinic and more careful monitoring of drug levels as well as clinical effect and toxicity in patients receiving the combination of these two agents" /><sentence text="" /></document>